The intestinal environment in health and disease - Recent insights on the potential of intestinal bacteria to influence human health

Current Pharmaceutical Design

Volumn 15, Issue 18, 2009, Pages 2051-2065

  Possemiers, Sam ^a   Grootaert, Charlotte ^a   Vermeiren, Joan ^a   Gross, Gabriele ^a,b   Marzorati, Massimo ^a   Verstraete, Willy ^a   Van de Wiele, Tom ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FLUOROURACIL; GHRELIN; GLUCAGON LIKE PEPTIDE; ORIVUDINE; PEPTIDE YY; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

APPETITE; BACTERIAL COLONIZATION; DRUG METABOLISM; ENTERITIS; GENE EXPRESSION; HEALTH STATUS; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; INTESTINE ABSORPTION; INTESTINE FLORA; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; MICROBIAL COMMUNITY; MICROBIAL METABOLISM; MOLECULAR INTERACTION; NONHUMAN; NUTRIENT UPTAKE; OBESITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; BACTERIA; DISEASE; HEALTH; HUMANS; INTESTINES; MICROBIOME; OBESITY; SYMBIOSIS; XENOBIOTICS;

EID: 68449086974     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788489159     Document Type: Review

References (160)

1. Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: The unseen majority. Proc Natl Acad Sci USA 1998; 95: 6578-83.
2. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-10.
3. Egert M, de Graaf AA, Smidt H, de Vos WM, Venema K. Beyond diversity: functional microbiomics of the human colon. Trends Microbiol 2006; 14: 86-91.
4. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-23.
5. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80: S147-71.
6. Dethlefsen L, Eckburg PB, Bik EM, Relman DA. Assembly of the human intestinal microbiota. Trends Ecol Evol 2006; 21: 517-23.
7. Conly JM, Stein K. Quantitative and qualitative measurements of vitamin K in human intestinal contents. Am J Gastroenterol 1992; 87: 311-6.
8. Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003; 69: 1920-7.
9. MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005; 307: 1920-5.
10. Elson CO, Cong Y, Qi F, Hershberg RM, Targan SR. Molecular Approaches to the role of the microbiota in inflammatory bowel disease. Ann NY Acad Sci 2006; 1072: 39-51.
11. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germfree mice. Proc Natl Acad Sci USA 2007; 104: 979-84.
12. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-9.
13. Zoetendal EG, Collier CT, Koike S, Mackie RI, Gaskins HR. Molecular ecological analysis of the gastrointestinal microbiota: A review. J Nutr 2004; 134: 465-72.
14. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-20.
15. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-48.
16. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006; 7: 688-93.
17. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-4.
18. Corthesy B, Gaskins HR, Mercenier A. Cross-talk between probiotic bacteria and the host immune system. J Nutr 2007; 137: 781S-90.
19. Dogi CA, Galdeano CM, Perdigon G. Gut immune stimulation by non pathogenic Gram(+) and Gram(-) bacteria. Comparison with a probiotic strain. Cytokine 2008; 41: 223-31.
20. Lu L, Walker WA. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium. Am J Clin Nutr 2001; 73: 1124S-30.
21. Hughes DT, Sperandio V. Inter-kingdom signalling: Communication between bacteria and their hosts. Nat Rev Microbiol 2008; 6: 111-20.
22. Kelly D, Conway S, Aminov R. Commensal gut bacteria: Mechanisms of immune modulation. Trends Immunol 2005; 26: 326-33.
23. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-41.
24. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449: 819-26.
25. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9.
26. Frances R, Munoz C, Zapater P, Uceda F, Gascon I, Pascual S, et al. Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53: 860-4.
27. Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, et al. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA 2005; 102: 10321-6.
28. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126: 520-8.
29. Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol 2006; 17: 204-10.
30. Gross G, van der Meulen J, Snel J, van der Meer R, Kleerebezem M, Niewold TA, et al. Mannose-specific interaction of Lactobacillus plantarum with porcine jejunal epithelium. FEMS Immunol Med Microbiol 2008; 54: 215-23.
31. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005; 115: 1260-7.
32. Niewold TA, Kerstens HH, van der Meulen J, Smits MA, Hulst MM. Development of a porcine small intestinal cDNA micro-array: characterization and functional analysis of the response to enterotoxigenic E. coli. Vet Immunol Immunopathol 2005; 105: 317-29.
33. Rodenburg W, Bovee-Oudenhoven IM, Kramer E, van der Meer R, Keijer J. Gene expression response of the rat small intestine following oral Salmonella infection. Physiol Genomics 2007; 30: 123-33.
34. Troost FJ, van Baarlen P, Lindsey P, Kodde A, de Vos WM, Kleerebezem M, et al. Identification of the transcriptional response of human intestinal mucosa to Lactobacillus plantarum WCFS1 in vivo. BMC Genomics 2008; 9: 374.
35. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881-4.
36. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 2008; 72: 728-+.
37. Sonnenburg JL, Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol 2006; 4: 2213-26.
38. Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 2006; 313: 1126-30.
39. Keilbaugh SA, Shin ME, Banchereau RF, McVay LD, Boyko N, Artis D, et al. Activation of RegIIIbeta/gamma and interferon gamma expression in the intestinal tract of SCID mice: An innate response to bacterial colonisation of the gut. Gut 2005; 54: 623-9.
40. Rodenburg W, Keijer J, Kramer E, Roosing S, Vink C, Katan MB, et al. Salmonella induces prominent gene expression in the rat colon. BMC Microbiol 2007; 7: 84.
41. Macpherson AJ, Geuking MB, McCoy KD. Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology 2005; 115: 153-62.
42. Armougom F, Raoult D. Use of pyrosequencing and DNA barcodes to monitor variations in Firmicutes and Bacteroidetes communities in the gut microbiota of obese humans. BMC Genom 2008; 9: 576.
43. Bron PA, Grangette C, Mercenier A, de Vos WM, Kleerebezem M. Identification of Lactobacillus plantarum genes that are induced in the gastrointestinal tract of mice. J Bacteriol 2004; 186: 5721-9.
44. Goldenberg O, Herrmann S, Marjoram G, Noyer-Weidner M, Hong G, Bereswill S, et al. Molecular monitoring of the intestinal flora by denaturing high performance liquid chromatography. J Microbiol Methods 2007; 68: 94-105.
45. Gross G, Wildner J, Schonewille A, Rademaker JL, van der Meer R, Snel J. Probiotic Lactobacillus plantarum 299v does not counteract unfavorable phytohemagglutinin-induced changes in the rat intestinal microbiota. Appl Environ Microbiol 2008; 74: 5244-9.
46. Jacobs DM, Deltimple N, van Velzen E, van Dorsten FA, Bingham M, Vaughan EE, et al. 1H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome. NMR Biomed 2007; 21: 615-26.
47. Klaassens ES, de Vos WM, Vaughan EE. Metaproteomics approach to study the functionality of the microbiota in the human infant gastrointestinal tract. Appl Environ Microbiol 2007; 73: 1388-92.
48. Li M, Wang BH, Zhang MH, Rantalainen M, Wang SY, Zhou HK, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008; 105: 2117-22.
49. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004; 303: 1662-5.
50. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453: 620-5.
51. Palmer C, Bik EM, Digiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol 2007; 5: E177.
52. Possemiers S, Bolca S, Eeckhaut E, Depypere H, Verstraete W. Metabolism of isoflavones, lignans and prenylflavonoids by intestinal bacteria: producer phenotyping and relation with intestinal community. FEMS Microbiol Ecol 2007; 61: 372-83.
53. Pretzer G, Snel J, Molenaar D, Wiersma A, Bron PA, Lambert J, et al. Biodiversity-based identification and functional characterization of the mannose-specific adhesin of Lactobacillus plantarum. J Bacteriol 2005; 187: 6128-36.
54. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Van der Meer R. Dietary fructooligosaccharides increase intestinal permeability in rats. J Nutr 2005; 135: 837-42.
55. Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 2008; 105: 20858-63.
56. van de Wiele T, Boon N, Possemiers S, Jabobs H, Verstraete W. Inulin-type fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. J Appl Microbiol 2007; 102: 452-60.
57. Altermann E, Russell WM, Azcarate-Peril MA, Barrangou R, Buck BL, McAuliffe O, et al. Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci USA 2005; 102: 3906-12.
58. Klaenhammer TR, Barrangou R, Buck BL, Azcarate-Peril MA, Altermann E. Genomic features of lactic acid bacteria effecting bioprocessing and health. FEMS Microbiol Rev 2005; 29: 393-409.
59. Kleerebezem M, Boekhorst J, van Kranenburg R, Molenaar D, Kuipers OP, Leer R, et al. Complete genome sequence of Lactobacillus plantarum WCFS1. Proc Natl Acad Sci USA 2003; 100: 1990-5.
60. Lambert JM, Bongers RS, Kleerebezem M. Cre-lox-based system for multiple gene deletions and selectable-marker removal in Lactobacillus plantarum. Appl Environ Microbiol 2007; 73: 1126-35.
61. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52: 827-33.
62. Marco ML, Bongers RS, de Vos WM, Kleerebezem M. Spatial and temporal expression of Lactobacillus plantarum genes in the gastrointestinal tracts of mice. Appl Environ Microbiol 2007; 73: 124-32.
63. Kaplan CW, Astaire JC, Sanders ME, Reddy BS, Kitts CL. 16S ribosomal DNA terminal restriction fragment pattern analysis of bacterial communities in feces of rats fed Lactobacillus acidophilus NCFM. Appl Environ Microbiol 2001; 67: 1935-9.
64. Wang RF, Beggs ML, Erickson BD, Cerniglia CE. DNA microarray analysis of predominant human intestinal bacteria in fecal samples. Mol Cell Probes 2004; 18: 223-34.
65. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57: 1605-15.
66. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 2008; 24: 4-10.
67. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008; 105: 2117-22.
68. Dalma-Weiszhausz DD, Warrington J, Tanimoto EY, Miyada CG. The affymetrix GeneChip platform: An overview. Methods Enzymol 2006; 410: 3-28.
69. van Hemert S, Ebbelaar BH, Smits MA, Rebel JM. Generation of EST and microarray resources for functional genomic studies on chicken intestinal health. Anim Biotechnol 2003; 14: 133-43.
70. Molly K, Woestyne MV, Verstraete W. Development of a 5-step multichamber reactor as a simulation of the human intestinal microbial ecosystem. Appl Microbiol Biotechnol 1993; 39: 254-8.
71. Possemiers S, Verthe K, Uyttendaele S, Verstraete W. PCR-DGGE-based quantification of stability of the microbial community in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol 2004; 49: 495-507.
72. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
73. Makivuokko HA, Saarinen MT, Ouwehand AC, Rautonen NE. Effects of lactose on colon microbial community structure and function in a four-stage semi-continuous culture system. Biosci Biotechnol Biochem 2006; 70: 2056-63.
74. Possemiers S, Rabot S, Espin JC, Bruneau A, Philippe C, Gonzalez-Sarrias A, et al. Eubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L.) into the potent phytoestrogen 8-prenylnaringenin in vitro and in the rat intestine. J Nutr 2008; 138: 1310-6.
75. Laube B, Winkler S, Ladstetter B, Scheller T, Schwarz LR. Establishment of a novel in vitro system for studying the interaction of xenobiotic metabolism of liver and intestinal microflora. Arch Toxicol 2000; 74: 379-87.
76. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 754-9.
77. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev 2008; 6: 349-62.
78. Marzorati M, Wittebolle L, Boon N, Daffonchio D, Verstraete W. How to get more out of molecular fingerprints: Practical tools for microbial ecology. Environ Microbiol 2008; 10: 1571-81.
79. Verstraete W. Microbial ecology and environmental biotechnology. ISME J 2007; 1: 4-8.
80. Tuohy KM, Hinton DJS, Davies SJ, Crabbe MJC, Gibson GR, Ames JM. Metabolism of Maillard reaction products by the human gut microbiota - implications for health. Mol Nutr Food Res 2006; 50: 847-57.
81. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008; 363: 1-25.
82. Ilett KF, Tee LBG, Reeves PT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Therapeut 1990; 46: 67-93.
83. Clifford MN. Diet-derived Phenols in plasma and tissues and their implications for health. Planta Med 2004; 70: 1103-14.
84. Walle T, Walle UK, Halushka PV. Carbon dioxide is the major metabolite of quercetin in humans. J Nutr 2001; 131: 2648-52.
85. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. Bioavailability of phytoestrogens. Br J Nutr 2003; 89: S45-58.
86. Possemiers S, Verstraete W, Van de Wiele T. In: Preedy VR, Ed. Estrogenicity of beer: The role of intestinal bacteria in the activation of the beer flavonoid isoxanthohumol. Oxford: Elsevier 2009; pp. 523-39.
87. Decroos K, Vanhemmens S, Cattoir S, Boon N, Verstraete W. Isolation and characterisation of an equol-producing mixed microbial culture from a human fecal sample and its activity under gastrointestinal conditions. Arch Microbiol 2005; 183: 45-55.
88. Possemiers S, Heyerick A, Robbens V, De Keukeleire D, Verstraete W. Activation of proestrogens from hops (Humulus lupulus L.) by intestinal microbiota; Conversion of isoxanthohumol into 8-prenylnaringenin. J Agric Food Chem 2005; 53: 6281-8.
89. Clavel T, Henderson G, Alpert CA, Philippe C, Rigottier-Gois L, Dore J, et al. Intestinal bacterial communities that produce active estrogen-like compounds enterodiol and enterolactone in humans. Appl Environ Microbiol 2005; 71: 6077-85.
90. Eeckhaut E, Struijs K, Possemiers S, Vincken JP, De Keukeleire D, Verstraete W. Metabolism of the lignan macromolecule into enterolignans in the gastrointestinal lumen as determined in the simulator of the human intestinal microbial ecosystem. J Agric Food Chem 2008; 56: 4806-12.
91. Bolca S, Possemiers S, Herregat A, Huybrechts I, Heyerick A, De Vriese S, et al. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr 2007; 137: 2242-6.
92. Bolca S, Possemiers S, Maervoet V, Huybrechts I, Heyerick A, Vervarcke S, et al. Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: A dietary intervention trial with fifty healthy post-menopausal Caucasian women. Br J Nutr. 2007; 98: 950-9.
93. Santos-Buelga C, Scalbert A. Proanthocyanidins and tannin-like compounds - nature, occurrence, dietary intake and effects on nutrition and health. J Sci Food Agric 2000; 80: 1094-117.
94. Gonthier MP, Verny MA, Besson C, Remesy C, Scalbert A. Chlorogenic acid bioavailability largely depends on its metabolism by the gut microflora in rats. J Nutr 2003; 133: 1853-9.
95. Humblot C, Murkovic M, Rigottier-Gois L, Bensaada M, Bouclet A, Andrieux C, et al. beta-Glucuronidase in human intestinal microbiota is necessary for the colonic genotoxicity of the food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline in rats. Carcinogenesis 2007; 28: 2419-25.
96. Bowes SG, Renwick AG. The intestinal metabolism and DNA-binding of benzo[a]pyrene in guinea pigs fed normal, high-fat and high-cholesterol diets. Xenobiotica 1986; 16: 543-53.
97. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998; 287: 791-9.
98. Huycke MM, Moore DR. In vivo production of hydroxyl radical by Enterococcus faecalis colonizing the intestinal tract using aromatic hydroxylation. Free Rad Biol Med 2002; 33: 818-26.
99. Van Tassell RL, Carman RJ, Kingston DG, Wilkins TD. Bacterial metabolism in humans of the carcinogen IQ to the direct acting mutagen hydroxy-IQ. Microb Ecol Health Dis 1989; 2: 123-9.
100. Humblot C, Combourieu B, Vaisanen ML, Furet JP, Delort AM, Rabot S. 1H nuclear magnetic resonance spectroscopy-based studies of the metabolism of food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline by human intestinal microbiota. Appl Environ Microbiol 2005; 71: 5116-23.
101. Van de Wiele T, Vanhaecke L, Boeckaert C, Peru K, Headley J, Verstraete W, et al. Human colon microbiota transform polycyclic aromatic hydrocarbons to estrogenic metabolites. Environ Health Perspect 2005; 113: 6-10.
102. Vanhaecke L, Vercruysse F, Boon N, Verstraete W, Cleenwerck I, De Wachter M, et al. Isolation and characterization of human intestinal bacteria capable of transforming the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Appl Environ Microbiol 2008; 74: 1469-77.
103. Vanhaecke L, Derycke L, Le Curieux F, Lust S, Marzin D, Verstraete W, et al. The microbial PhIP metabolite 7-hydroxy-5-methyl-3-phenyl-6,7,8,9-tetrahydropyrido [3 ′,2 ′: 4,5]imidazo[1,2-a]pyrimidin-5-ium chloride (PhIP-M1) induces DNA damage, apoptosis and cell cycle arrest towards Caco-2 cells. Toxicol Lett 2008; 178: 61-9.
104. Meyer J, Michalke K, Kouril T, Hensel R. Volatilisation of metals and metalloids: An inherent feature of methanoarchaea? Syst Appl Microbiol 2008; 31: 81-7.
105. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292: 1115-8.
106. Villarini M, Caldini G, Moretti M, Trotta F, Pasquini R, Cenci G. Modulatory activity of a lactobacillus casei strain on 1.2-dimethylhydrazine-induced genotoxicity in rats. Environ Mol Mutagen 2008; 49: 192-9.
107. Lhoste EF, Nugon-Baudon L, Lory S, Meslin JC, Andrieux C. The fermentation of lactulose in rats inoculated with Clostridium paraputrificum influences the activities of liver and intestinal xenobiotic-metabolising enzymes. J Sci Food Agric 2001; 81: 1397-404.
108. Humblot C, Lhoste E, Knasmuller S, Gloux K, Bruneau A, Bensaada M, et al. Protective effects of Brussels sprouts, oligosaccharides and fermented milk towards 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced genotoxicity in the human flora associated F344 rat: Role of xenobiotic metabolising enzymes and intestinal microflora. J Chromatogr B 2004; 802: 231-7.
109. Mikov M. The metabolism of drugs by the gut flora. Eur J Drug Metab Pharmacokinet 1994; 19: 201-7.
110. Li HK, Ni Y, Su MM, Qiu YP, Zhou MM, Qiu MF, et al. Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. J Proteome Res 2007; 6: 1364-70.
111. Wyatt SB, Winters KP, Dubbert PM. Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006; 331: 166-74.
112. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-5.
113. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature 2006; 444: 1022-3.
114. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-131.
115. Delzenne NM, Cani PD, Neyrinck AM. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: Experimental data. J Nutr 2007; 137: 2547S-51.
116. Egan JM, Margolskee RF. Taste cells of the gut and gastrointestinal chemosensation. Mol Interv 2008; 8: 78-81.
117. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 2008; 295: E1160-6.
118. Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, Muller M, et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem 2006; 281: 934-44.
119. Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin YB, Soukas A, et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 2000; 20: 5343-9.
120. Delzenne NM, Kok N, Fiordaliso M, Deboyser D, Goethals F, Roberfroid MB. Dietary fructo-oligosaecharides modifies lipid metabolism in rats. Am J Clin Nutr 1993; 57: 8205.
121. Hanai JI, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao JH, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117: 3940-51.
122. St-Onge M-P, Farnworth ER, Jones PJH. Consumption of fermented and nonfermented dairy products: Effects on cholesterol concentrations and metabolism. Am J Clin Nutr 2000; 71: 674-81.
123. Todesco T, Rao AV, Bosello O, Jenkins DJA. Propionate lowers blood glucose and alters lipid-metabolism in healthy subjects. Am J Clin Nutr 1991; 54: 860-5.
124. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia. A nested case-control analysis. Diabetes Care 2008; 31: 2086-91.
125. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 2006; 55: 1484-90.
126. Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, et al. Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. FASEB J 2004; 18: 439-56.
127. Cani PD, Hoste S, Guiot Y, Delzenne NM. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr 2007; 98: 32-7.
128. Gee JM, Johnson IT. Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. Nutrition 2005; 21: 1036-43.
129. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-83.
130. Cani PD, Dewever C, Delzenne NM. Inulin-type fructans modulate gastrointestinal peptides involved in appetite regulation (glucagon-like peptide-1 and ghrelin) in rats. Br J Nutr 2004; 92: 521-6.
131. Massimino SP, McBurney MI, Field CJ, Thomson ABR, Keelan M, Hayek MG, et al. Fermentable dietary fiber increases GLP-1 secretion and improves glucose homeostasis despite increased intestinal glucose transport capacity in healthy dogs. J Nutr 1998; 128: 1786-93.
132. Yoshida K, Shimizugawa T, Ono M, Furukawa H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res 2002; 43: 1770-2.
133. Williams CM. Postprandial lipid metabolism: Effects of dietary fatty acids. Proc Nutr Soc 1997; 56: 679-92.
134. Berggren A, Nyman EMGL, Lundquist I, Björck IME. Influence of orally and rectally administered propionate on cholesterol and glucose metabolism in obese rats. Br J Nutr 1996; 76: 287-94.
135. Lin Y, Vonk RJ, Slooff MJ, Kuipers F, Smit MJ. Differences in propionate-induced inhibition of cholesterol and triacylglycerol synthesis between human and rat hepatocytes in primary culture. Br J Nutr 1995; 74: 197-207.
136. Bongaerts GP, Severijnen RS, Tangerman A, Verrips A, Tolboom JJ. Bile acid deconjugation by Lactobacilli and its effects in patients with a short small bowel. J Gastroenterol 2000; 35: 801-4.
137. Nakajima H, Suzuki Y, Kaizu H, Hirota T. Cholesterol lowering activity of ropy fermented milk. J Food Sci 1992; 57: 1327-9.
138. Pulusani SR, Rao DR. Whole body, liver and plasma cholesterol levels in rats fed Thermophilus bulgaricus and acidophilus milks. J Food Sci 1983; 48: 280-1.
139. Richelsen B, Kristensen K, Pedersen SB. Long-term (6 months) effect of a new fermented milk product on the level of plasma lipoproteins - a placebo-controlled and double blind study. Eur J Clin Nutr 1996; 50: 811-5.
140. Gilliland SE, Nelson CR, Maxwell C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol 1985; 49: 377-81.
141. Beena A, Prasad V. Effect of yogurt and bifidus yogurt fortified with skim milk powder, condensed whey and lactose-hydrolysed condensed whey on serum cholesterol and triacylglycerol levels in rats. J Dairy Res 1997; 64: 453-7.
142. Mohan B, Kadirvel R, Natarajan A, Bhaskaran M. Effect of probiotic supplementation on growth, nitrogen utilization and serum cholesterol in broilers. Br Poult Sci 1996; 37: 395-401.
143. Xiao JZ, Kondo S, Takahashi N, Miyaji K, Oshida K, Hiramatsu A, et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 2003; 86: 2452-61.
144. Hentges DJ. Biotransformation of bile acids and cholesterol by the intestinal microflora. New York: Academic Press 1983.
145. Fiordaliso MF, Kok N, Desager JP, Goethals F, Deboyser D, Roberfroid MB, et al. Dietary oligofructose lowers triacylglycerols, phospholipids and cholesterol in serum and very low density lipoproteins of rats. Lipids 1995; 30: 163-7.
146. Trautwein EA, Rieckhoff D, Erbersdobler HF. Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamsters. J Nutr 1998; 128: 1937-43.
147. Williams CM, Jackson KG. Inulin and oligofructose: Effects on lipid metabolism from human studies. Br J Nutr 2002; 87: S261-4.
148. Cheng H-H, Lai M-H. Fermentation of resistant rice starch produces propionate reducing serum and hepatic cholesterol in rats. J Nutr 2000; 130: 1991-5.
149. Venter CS, Vorster HH, Cummings JH. Effects of dietary propionate on carbohydrate and lipid metabolism in healthy volunteers. Am J Gastroenterol 1990; 85: 549-53.
150. Towle HC. Glucose and cAMP: Adversaries in the regulation of hepatic gene expression. Proc Natl Acad Sci USA 2001; 98: 13476-8.
151. Hooper LV, Midtveld T, Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Ann Rev Nutr 2002; 22: 283-307.
152. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol 2005; 185: 457-65.
153. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999; 20: 805-75.
154. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 2004; 92: 757-61.
155. Zaneveld J, Turnbaugh PJ, Lozupone C, Ley RE, Hamady M, Gordon JI, et al. Host-bacterial coevolution and the search for new drug targets. Curr Opin Chem Biol 2008; 12: 109-14.
156. Lujan SA, Guogas LM, Ragonese H, Matson SW, Redinbo MR. Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase. Proc Natl Acad Sci USA 2007; 104: 12282-7.
157. Cani PD, Delzenne NM. Gut microflora as a target for energy and metabolic homeostasis. Curr Opin Clin Nutr Metab Care 2007; 10: 729-34.
158. Corcoran BM, Stanton C, Fitzgerald G, Ross R P. Life under stress: The probiotic stress response and how it may be manipulated. Curr Pharm Des 2008; 14(14): 1382-99.
159. O'Sullivan DJ. Genomics can advance the potential for probiotic cultures to improve liver and overall health. Curr Pharm Des 2008; 14(14): 1376-81.
160. Singh SB. Pelaez F. Biodiversity, chemical diversity and drug discovery. Prog Drug Res 2008; 65: 141, 143-74.